Enrollment in the Phase 1/2 ASTRA study is set to start in the first half of 2025. The study will observe the safety and ...

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...

Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

The sickle cell gene therapies developed by Bluebird Bio and Vertex will be the first to be offered under the new scheme. A major issue with gene and cell therapies is the upfront cost. While these ...